[Treatment of chronic arterial circulatory disorders. Double blind trial with Trental 400 (author's transl)].
For the objective determination of its efficacy, Trental 400 was examined against placebo in a double blind trial in 40 patients with chronic peripheral circulatory disorders and concomitant symptoms of cerebro-vascular insufficiency typical of age. Treatment lasted 7 to 8 weeks with a dosage of 1 tablet 3 times a day. Trental 400 was significantly more effective than placebo in the treatment of peripheral and cerebral disorders. The preparation was well tolerated, subjectively and objectively.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004777:Environment; D005260:Female; D005684:Gait; D006801:Humans; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000009:adverse effects; D010919:Placebos
D010919:Placebos; D010431:Pentoxifylline
Zur Behandlung chronischer arterieller Durchblutungs-störungen. Doppelblindversuch mit Trental 400